Obnyx Capsule contains Enzalutamide 40 mg, a nonsteroidal antiandrogen agent indicated primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide functions by inhibiting multiple steps in the androgen receptor signaling pathway, including androgen binding, receptor nuclear translocation, and DNA interaction, thereby reducing tumor cell proliferation driven by androgen stimulation. This mechanism makes it effective in patients whose disease progresses despite androgen deprivation therapy. Obnyx Capsule is administered orally, typically once daily, with or without food, under the supervision of a healthcare professional. Clinical studies have demonstrated that Enzalutamide significantly improves overall survival, delays disease progression, and reduces skeletal-related events in men with advanced prostate cancer. Common adverse effects include fatigue, hypertension, hot flushes, and headache, while serious but less frequent risks involve seizures and cardiovascular events. Prior to initiating therapy, patients should be evaluated for seizure risk and cardiovascular status. Regular monitoring of liver function tests and blood pressure is recommended during treatment. Obnyx Capsule should be used cautiously in patients with a history of seizures or conditions predisposing to seizures. It is contraindicated in women and pediatric populations. Patient adherence and periodic assessment of therapeutic response are essential for optimal clinical outcomes.